case_images: PMC6681578_01
case_images: Evolution of serum flecainide concentration over time. IFE: intravenous fat emulsion. The terminal half-life (t1/2) elimination of flecainide was calculated over the first four hours (3.7 hours) following the introduction of CytoSorb  hemoadsorption and over the eighteen following hours (23.4 hours). Note that the terminal half-life was influenced by the combination of CytoSorb , CVVHDF, and ECLS clearances and of metabolic (hepatic) clearance.
case_images: CRIC2019-1905871.001.jpg
case_images: PMC6681578_01_CRIC2019-1905871.001.jpg
case_images: fig1
case_images: The detailed toxicokinetics of flecainide in relationship with the epuration technique are presented in Figures 1 and 2.
case_images: Determination of the serum flecainide concentration at the inlet (IN) and outlet (OUT) of the CytoSorb  hemoadsorption circuit. The extraction ratio (%) could be expressed as (concentration IN-concentration OUT/concentration IN). Blood flow in the circuit was 200 ml/min. Plasma flow rate was expressed as blood flow rate x (1-haematocrit).
case_images: CRIC2019-1905871.002.jpg
case_images: PMC6681578_01_CRIC2019-1905871.002.jpg
case_images: fig2
case_images: The detailed toxicokinetics of flecainide in relationship with the epuration technique are presented in Figures 1 and 2.